Alzheimer's Disease Care Guide

The most common first sign is memory loss that disrupts daily life — specifically difficulty retaining newly learned information. Other early signs: asking the same question repeatedly, difficulty with familiar tasks (cooking, managing bills), confusion about time or place, and subtle personality changes like increased suspicion or social withdrawal. If you notice 2 or more of these signs persisting for weeks, request a cognitive evaluation from the primary care physician.

Dementia is the broader term for a syndrome of cognitive decline affecting memory, thinking, behavior, and daily function. Alzheimer's disease is the most common cause of dementia, accounting for 60–80% of all dementia cases. Other causes include vascular dementia (strokes), Lewy body dementia, and frontotemporal dementia. A diagnosis of 'Alzheimer's disease' means amyloid plaques and tau tangles are the confirmed underlying cause.

The average survival after an Alzheimer's diagnosis is 8–10 years, though it ranges from 4 to 20 years depending on age at diagnosis, overall health, and other conditions. People diagnosed in their 60s (early-onset) may live 15–20 years. People diagnosed in their 80s may live 3–5 years. The disease always progresses — there is currently no cure — but the rate of progression varies significantly between individuals.

Memory care is typically needed when: (1) wandering or elopement risk is present; (2) behavioral symptoms (aggression, delusions, sundowning) exceed what family or standard assisted living staff can manage; (3) the person requires 24-hour supervision for all activities of daily living; or (4) a caregiver is showing signs of burnout. This typically corresponds to Stage 5–6. Signs it's time: repeated wandering attempts, inability to recognize familiar people, incontinence that can't be managed at home.

Medicare does NOT cover long-term memory care room and board. Medicare Part B covers cognitive assessments, physician visits, and the new disease-modifying drugs Leqembi and Kisunla for eligible early-stage patients with confirmed amyloid pathology. Medicare covers short-term skilled nursing care after a 3-day hospital stay (up to 100 days). For long-term memory care costs, Medicaid is the primary payer for low-income seniors who meet eligibility requirements.

It depends on the state. Some states cover memory care personal care through Medicaid waivers (Washington COPES, Oregon K-Plan, Minnesota Elderly Waiver) but NOT room and board. In most states, Medicaid covers nursing home care with a dementia unit as the primary residential option for late-stage Alzheimer's. Use AllyKin's state Medicaid guides to check your specific state's program.

The average cost of memory care in the United States is approximately $6,000–$6,500 per month in 2026. Costs range from $4,200/month in affordable Southern and Midwestern markets to $10,000+/month in California and New York. Memory care is typically 20–40% more expensive than standard assisted living due to higher staffing ratios, specialized programming, and secured environments.

Two FDA-approved disease-modifying therapies are available: Lecanemab (Leqembi) — approved January 2023, slows cognitive decline by 27% in early-stage patients; and Donanemab (Kisunla) — approved July 2024, slows decline by 35% in early-stage patients. Both are IV infusion therapies for Stage 3–4 (early symptomatic) Alzheimer's only, requiring confirmed amyloid via PET or CSF testing. Medicare covers both for eligible patients. Neither is appropriate for mid-to-late stage disease.